Amgen Wins Preliminary Injunction to Block Colorado From Imposing Price Cap on Arthritis Drug
MT Newswires Live
Jul 02
Amgen (AMGN) won a preliminary injunction to prevent Colorado state from imposing price caps on the company's rheumatoid arthritis drug, Enbrel, according to the text of the court ruling promulgated Wednesday.
According to the decision, Amgen would likely face significant and irreparable harm from charging lower prices.
"The state's interest in helping citizens afford Enbrel is legitimate, and it has a number of ways to try to do so," the ruling read. "But one way it cannot do so under the binding precedent of the Federal Circuit, is by capping the price of a patented drug."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.